Shopping Cart

Expired activity

Please go to the PowerPak homepage and select a course.

FACULTY

Dhiren K. Patel, PharmD, CDE, BC-ADM, BCACP
Associate Professor of Pharmacy Practice
School of Pharmacy
MCPHS University
Clinical Pharmacy Specialist
VA Boston Healthcare System
Boston, MA

DIABETES PROGRAM PLANNER/PHARMACY TECHNICIAN ADVISOR

Susan Sloane, RPh, CDE, CPT

FINANCIAL DISCLOSURE

Dhiren K. Patel, PharmD, CDE, BC-ADM, BCACP has indicated the following relevant affiliations or financial relationships with a commercial interest related to the content of this activity: Consultant/Advisory Board for Novo Nordisk and Sanofi; member of the speaker's bureau for Novo Nordisk and Sanofi.

The following reviewer, Joshua Neumiller, PharmD, CDE, hereby discloses the following financial relationships or relationships to products or devices with a commercial interest related to the content of this activity: receives grant/research support from AstraZeneca, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk; consultant for Janssen Pharmaceuticals, Inc. and Sanofi; a member of the speakers bureau for Novo Nordisk.

The following reviewers, Laura K. Stinson, PharmD and Monica F. Roberts, PharmD have nothing to disclose.

Susanne Batesko, RN, BSN, and Robin Carrino, and Susan Sloane, RPh, CDE, CPT, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.

ACCREDITATION STATEMENTS

PHARMACY

Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-0000-16-024-H01-T

Credits: 2.0 hours (0.20 ceu)
Published: December 9, 2016
Last Review: May 30, 2018
Expires: May 1, 2019
Type of Activity: Knowledge
Media: Internet

Fee Information: $4.50

Estimated time to complete activity: 120 minutes

TARGET AUDIENCE

This accredited activity has been designed for pharmacy technicians.

HOW TO EARN CREDIT

During the period December 9, 2016 through May 1, 2019 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the post-test and the evaluation form. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on Grade Exam at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.

GOAL

To familiarize pharmacy technicians with non-insulin injectable agents available for the management of diabetes and discuss the roles of these agents in diabetes treatment.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants should be better able to:

1. Discuss the roles of non-insulin injectable agents for achieving treatment goals in patients with type 2 diabetes;
2. Recognize the hierarchy of non-insulin injectable agents within current treatment recommendations;
3. Define the incretin effect and how it relates to the mechanism of action (MOA) of non-insulin injectable agents;
4. Discuss the MOA, adverse effects, and potential drug interactions associated with the use of non-insulin injectable agents; and
5. Explain Risk Evaluation and Mitigation Strategy (REMS) programs related to non-insulin injectable agents.

REQUIRED COMPUTER HARDWARE/SOFTWARE

Please ensure the computer system you plan to use meets the following minimum requirements:

• Operating System: Windows 98 or higher & Macintosh 2.2 or higher
• Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
• Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
• Peripherals: Computer speakers or headphones
• Monitor Screen Resolution: 320 x 480 or higher
• Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

Disclosure of Unlabeled Use and Disclaimer

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without an evaluation of their patients' conditions and current medications, including the identification of possible contraindications regarding the dangers of use and a review of any applicable manufacturer's product information, as well as a comparison with the recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this monograph have not been evaluated by the FDA. Nutritional products discussed are not intended for the diagnosis, treatment, cure, or prevention of any disease.